Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 12/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893299 | 1.00 | CPB2 (0.39) | CPB2SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL19447714 | 1.00 | CPB2 (0.39) | CPB2SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL14630714 | 1.00 | CPB2 (0.39) | CPB2SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL14630711 | 1.00 | CPB2 (0.39) | CPB2SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL14631226 | 0.93 | CPB2 (0.38) | CPB2SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL14631230 | 0.93 | CPB2 (0.38) | CPB2SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL14631228 | 0.93 | CPB2 (0.38) | CPB2SIGMAR1MEN1GAAKMT2A | |
| SCHEMBL28336007 | 0.92 | CPB2 (0.36) | CPB2SIGMAR1GFERSTK17BSTK17A | |
| SCHEMBL19159434 | 0.92 | CPB2 (0.36) | CPB2SIGMAR1GFERSTK17BSTK17A | |
| SCHEMBL14653711 | 0.92 | CPB2 (0.36) | CPB2SIGMAR1GFERSTK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2548871-B1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9340531-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-17 | — | — | US | disclosed |
| US-20140178349-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-26 | — | — | US | disclosed |
| US-8609710-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-05 | — | — | US | disclosed |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | disclosed |
| EP-2548871-A1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | CPB2 258/4885SIGMAR1 809/4885MEN1 3430/4885 |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | CPB2 258/4885SIGMAR1 809/4885MEN1 3430/4885 |
| US-20140178349-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | CPB2 258/4885SIGMAR1 809/4885MEN1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.